Entrada Therapeutics (NASDAQ: TRDA) — Perfil da empresa, notícias e dados financeiros
Entrada Therapeutics develops innovative therapies to engage intracellular targets for treating serious diseases, enhancing patient care.
Entrada Therapeutics
Entrada Therapeutics (NASDAQ:TRDA) is a biotechnology firm focused on the development of innovative therapies. The company specializes in creating drugs designed to engage intracellular targets, aiming to treat a broad range of diseases, including neuromuscular conditions and other serious ailments. Entrada Therapeutics is leveraging its proprietary platform to advance a portfolio of oligonucleotide and peptide therapeutics aimed at addressing unmet medical needs. With a commitment to science and patient care driving its operations, the firm is dedicated to pushing the boundaries of medicine to improve the lives of patients worldwide.
Resumo
Operações
Produtos e/ou serviços de Entrada Therapeutics
- Developing an intracellular biologics delivery platform aimed at transforming the treatment of devastating diseases.
- Focusing on a Duchenne Muscular Dystrophy (DMD) program, leveraging their platform to address this genetic disorder.
- Advancing programs targeting Myotonic Dystrophy Type 1, utilizing novel therapeutics for this neuromuscular disease.
- Creating a broad pipeline of endosomal escape vehicle (EEV™)-fueled therapies for various diseases.
- Offering research and development services to create custom intracellular delivery solutions for biopharmaceutical companies.
- Exploring potential treatments for other rare diseases through their proprietary technology platform.
equipe executiva do Entrada Therapeutics
- Dipal DoshiCEO & Director
- Nathan J. DowdenPresident & COO
- Natarajan SethuramanPresident of Research & Development
- Kory James WentworthCFO & Treasurer
- Jared CohenGeneral Counsel
- Karla MacDonaldChief Corporate Affairs Officer
- Kevin HealySenior Vice President of Regulatory Affairs
- Sandeep BasnetHead of Information Technology
Últimas notícias sobre a Entrada Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Entrada Therapeutics, em USD.
- Cap. de mercado
- 171,7 mi
- Receita (TTM)
- 4,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -4.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 25,4 mi | -156 mi | -143,8 mi | |
| 210,8 mi | 47 mi | 65,6 mi | |
| 129 mi | -3,2 mi | -6,7 mi | |
| 25,3 mi | -97,2 mi | -87,5 mi |